



PRESS RELEASE

Hikma awarded Best Company in an Emerging Market

London, 03 December 2015 – Hikma Pharmaceuticals PLC, the fast growing multinational pharmaceutical group, is pleased to announce that it was the recipient of the “Best Company in an Emerging Market Award” at the 11th annual SCRIP Awards held in London on 2 December 2015. The award was given in recognition of Hikma’s strong track record of growth and excellent operational performance across its businesses.

-- ENDS --

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal, VP Corporate Strategy and Investor Relations
Zeena Murad, Investor Relations Manager

+44 (0)20 7399 2760/ +44 7776 477050
+44 (0) 20 7399 2768/ +44 7771 665277

FTI Consulting

Ben Atwell/ Matthew Cole

+44 (0)20 3727 1000

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Injectables”, “Branded” and “Generics”, based principally in the United States, the Middle East and North Africa (“MENA”) and Europe. In 2014, Hikma achieved revenues of \$1,489 million and profit attributable to shareholders of \$299 million.